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Children with sickle cell anemia (SCA) and conditional transcranial Doppler (TCD) ultrasound
velocities (170-199 cm/sec) may develop stroke. However, with limited available clinical data, the
current standard of care for conditional TCD velocities is observation. The efficacy of
hydroxyurea in preventing conversion from conditional to abnormal TCD (≥200 cm/sec), which
confers a higher stroke risk, has not been studied prospectively in a randomized trial. Sparing
Conversion to Abnormal TCD Elevation (SCATE #NCT01531387) was an NHLBI-funded Phase
III multicenter international clinical trial comparing alternative therapy (hydroxyurea) to standard
care (observation) to prevent conversion from conditional to abnormal TCD velocity in children
with SCA. SCATE enrolled 38 children from the United States, Jamaica, and Brazil [HbSS (36),
HbSβ0-thalassemia (1), and HbSD (1), median age 5.4 years (range, 2.7-9.8)]. Due to slow patient
accrual and administrative delays, SCATE was terminated early. In an intention-to-treat analysis,
the cumulative incidence of abnormal conversion was 9% (95% CI 0 to 35%) in the hydroxyurea
arm and 47% (95% CI 6 to 81%) in observation arm at 15 months (p=0.16). In post-hoc analysis
according to treatment received, significantly fewer children on hydroxyurea converted to
abnormal TCD velocities, compared to observation (0% versus 50%, p=0.02). After a mean of
10.1 months, a significant change in mean TCD velocity was observed with hydroxyurea
treatment (−15.5 versus +10.2 cm/sec, p=0.02). No stroke events occurred in either arm.
Hydroxyurea reduces TCD velocities in children with SCA and conditional velocities.

Keywords
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Since the implementation of screening programs with transcranial Doppler examinations, the
number of first strokes in children with sickle cell anemia (SCA) has significantly
decreased. Identification of high risk patients (abnormal time-averaged mean velocity,
TAMV ≥ 200 cm/sec) followed by chronic blood transfusion therapy, has effectively
prevented most primary strokes.(1;2) Patients with abnormal TCD velocities are at highest
risk for developing cerebrovascular accidents; however, stroke events can also occur among
children whose last screening TCD examinations document conditional velocities (TAMV
170 - 199 cm/sec).(3;4) Although their risk of primary stroke is lower relative to patients
with abnormal TCD velocities (2 - 5% versus 9% per year), there are more patients with
conditional than abnormal TCD velocities (prevalence 17% versus 9%), and the absolute
number of children who might develop stroke is roughly equivalent between these two
screening categories.(3;5-7)
Although conditional TCD velocities represent a moderate risk for developing primary
stroke,(3;6) the current approach is clinical observation without specific disease-modifying
therapy. However, the risk of TCD conversion from conditional to abnormal velocities is
substantial and ranges from 15-55%.(7) Once conversion occurs, the established treatment is
chronic transfusion therapy,(4) posing a substantial burden to patients and families,
especially in resource-limited nations with an inadequate or less safe blood supply.
Am J Hematol. Author manuscript; available in PMC 2016 December 01.
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There is evidence that hydroxyurea can reduce TCD velocities in children with SCA,(8-13)
but further investigation is necessary to define the efficacy of hydroxyurea for preventing
conversion from conditional to abnormal TCD velocities, thereby preventing the transition
from moderate to high stroke risk category. Successfully preventing conversion to abnormal
TCD velocities with hydroxyurea would avoid exposure to prolonged blood transfusion and
its known complications (e.g., iron overload, alloimmunization, and infections). Prevention
of abnormal TCD conversion would, therefore, represent a significant improvement in the
medical management of children with SCA at moderate risk for stroke, and ultimately
reduce medical costs while simultaneously providing an established effective preventive
treatment for other sickle-related medical complications (e.g., painful events).

Author Manuscript

Sparing Conversion to Abnormal TCD Elevation (SCATE, Clinical trials.gov
NCT01531387) was a National Heart, Lung, and Blood Institute (NHLBI)-funded Phase III
multicenter international randomized clinical trial that compared alternative therapy
(hydroxyurea) to standard care (observation) to prevent conversion of TCD velocities from
the conditional to the abnormal range in children with SCA. SCATE enrolled children from
the United States (US), Jamaica, and Brazil. This study was terminated early due to slow
patient accrual and a low likelihood of reaching the primary study endpoint. However, even
with challenges of low patient accrual and regulatory difficulties that limited the number of
participants who actually received hydroxyurea therapy, a significant reduction in TCD
velocities and abnormal TCD conversion were observed in the hydroxyurea-treated group.
These findings suggest that hydroxyurea represents a potential treatment choice for children
with conditional TCD velocities, to help reduce the risk of first stroke.

METHODS
Author Manuscript

Patient Enrollment

Author Manuscript

Children 2-11 years of age with SCA (HbSS, HbSβ0-thalassmia, HbSOArab, or HbSD) and
conditional TCD velocities were recruited between May 2012 and August 2013 at three
sites: St. Jude Children’s Research Hospital (St. Jude), Memphis, TN, US; Sickle Cell Unit,
Tropical Medicine Research Institute (TMRI), University of the West Indies, Kingston,
Jamaica; and Instituto de Hematologia Arthur Siqueira Cavalcanti (HEMORIO), Rio de
Janeiro, RJ, Brazil (recruitment brochure provided as supplemental material). To meet study
eligibility, a screening TCD exam with conditional TCD velocity was required within 3
months of enrollment. Participants were excluded for prior history of abnormal TCD
velocities or clinical stroke, red blood cell transfusion within 2 months of enrollment,
concurrent use of another anti-sickling medication, or contra-indication to hydroxyurea
therapy (allergy, pregnancy, renal insufficiency). In addition, patients were temporarily
excluded from enrollment for profound anemia and/or cytopenias [hemoglobin (Hb)
concentration <6 g/dL, absolute reticulocyte count (ARC) <100 × 109/L with Hb
concentration <8.0 gm/dL, white blood cell count (WBC) <3.0 × 109/L, absolute neutrophil
count (ANC) <1.0 × 109/L, or platelet count <100 × 109/L]. All participants received
standard age-appropriate care for SCA (penicillin prophylaxis, pneumococcal immunization,
and disease education) as per local standards of care.

Am J Hematol. Author manuscript; available in PMC 2016 December 01.
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TCD Exam Procedure and Study Coordination
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SCATE was a Phase III, randomized, open label, partially masked, multi-center,
international, prospective trial of hydroxyurea versus observation for children with SCA and
centrally confirmed conditional TCD velocities. The study was partially masked in the
following fashion: (1) all site TCD examiners and central TCD reviewers were masked to
the assigned treatment arm; and (2) all site clinicians were masked to the participants’ serial
TCD results.

Author Manuscript

All three sites used a standardized TCD examination protocol with identical equipment
(Sonaratek TCD system, software version 6.68, Middleton, WI). The TCD examiners from
each site received standardized training, and all were required to pass a certification process
to ensure proficiency in performing the examinations according to the SCATE protocol. The
TAMV was obtained bilaterally in five arteries: middle cerebral artery (MCA), anterior
cerebral artery (ACA), posterior cerebral artery (PCA), internal carotid artery (ICA), and
internal carotid bifurcation (Bif). All exams were scored locally and sent electronically to
the Data Coordinating Center (DCC) by secure data transfer, and then de-identified and
uploaded to the TCD Core for review and scoring.

Author Manuscript

Pre-enrollment screening TCD exams were performed at each clinical site as per normal
practice. When a conditional TCD velocity was identified, the child and family were
approached regarding enrollment in the trial. After informed consent, this exam was
reviewed centrally to confirm the conditional velocity. Additional TCD exams were then
performed to document a second conditional velocity. Two independent exams with
conditional velocities were required within 6 months to proceed to randomization. Once
randomized, follow-up TCD exams were performed every 3 months thereafter
(supplemental Figure 1). All TCD exams were evaluated by the TCD Core and masked to
study site, subject demographics, and clinical status.
The SCATE study used a remote internet-based data capture system with secure data entry
and storage in a central database maintained by the DCC. Hydroxyurea was provided in
capsules of different sizes (300 mg, 400 mg, and 500mg) to facilitate dosing and were
purchased from Bristol-Myers Squibb (New York, NY). Hydroxyurea powder was obtained
from UPM Pharmaceuticals (Baltimore, MD) and used for reconstitution as a liquid
formulation (100 mg/mL).(14) A Central Pharmacy distributed the study drug (capsules and
powder) to all sites and monitored drug expiration.

Author Manuscript

The Medical Coordinating Center (MCC) ensured quality of the data, timely data entry,
guidance to sites in following the protocol with regards to hydroxyurea dosing, and ongoing
monitoring of adverse events. The study was approved by the Institutional Review Board of
all participating institutions, and informed consent was signed by all guardians of the
children, prior to any study-related activities. An independent Data Safety Monitoring Board
evaluated the unblinded study results for safety and study endpoints.
Study Endpoints
The primary endpoint of the SCATE trial was the cumulative incidence of conversion to
abnormal maximum TAMV velocities (in any of the 10 vessels measured). Secondary
Am J Hematol. Author manuscript; available in PMC 2016 December 01.
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endpoints included: (1) changes in serial TCD velocities; (2) cumulative incidence of
neurological and non-neurological acute events including stroke; and (3) health-related
quality of life (HRQOL). The MCC informed the site clinicians once subjects met the
primary endpoint of the study (conversion to abnormal maximum TAMV velocities), at
which point the subject was removed from the study.
Study Procedures and Evaluation

Author Manuscript

After randomization, participants received hydroxyurea treatment or observation, planned
for a total of 30 months. Monthly physical exams and laboratory tests (monthly complete
blood counts and reticulocyte counts and bi-monthly chemistries) were performed locally.
Hb identification using high performance liquid chromatography with quantitation of HbA,
HbS, and fetal Hb (HbF) was obtained quarterly and centrally analyzed. For subjects
randomized to the alternative (hydroxyurea) arm, the initial drug dose was 20 mg/kg/day
and escalated to maximum tolerated dose (MTD) at 5 mg/kg/day increments to a dose not to
exceed 35 mg/kg/day.(15) MTD was defined as the daily dose leading to mild neutropenia
(ANC 2.0 to 4.0 × 109/L), without reaching pre-defined thresholds of hematological toxicity,
defined as ANC <1.0 × 109/L, Hb concentration <7.5 gm/dL with absolute reticulocyte
count <100 × 109/L, platelets <80 × 109/L, or ARC <80 × 109/L with hemoglobin
concentration <8.5 gm/dL. Hydroxyurea dose was held for one week if hematological
toxicity occurred, and restarted at the same dose or with a 10% reduction if toxicity recurred.
Hydroxyurea adherence (%) was assessed through calculation of returned doses, divided by
the dispensed amount, at every study visit.
Statistical Considerations

Author Manuscript
Author Manuscript

The SCATE study was designed to have a 5% chance (α = 0.05) of falsely concluding that
hydroxyurea reduces the cumulative incidence of conversion to abnormal TCD velocity,
when in fact there is no difference between the hydroxyurea and standard treatment groups;
and at least 80% (= 1 − ß) power to correctly conclude that hydroxyurea reduces the
cumulative incidence of conversion to abnormal TCD velocity, given the true effect is at
least a three-fold reduction in cumulative incidence after 30-months. Assuming a 5% per
year dropout rate, 100 randomized participants were required to demonstrate that
hydroxyurea reduces the cumulative incidence of conversion to abnormal TCD velocity.
Children were randomized at a 1 to 1 ratio and used an adaptive blocked randomization
algorithm. The intention-to-treat principle was followed and all eligible, randomized
participants were analyzed as randomized, in the primary analysis. As a secondary post-hoc
analysis, participants were analyzed according to the actual treatment received (hydroxyurea
versus observation), since two children were randomized but did not receive treatment with
hydroxyurea due to unavailability of study drug at one site. The exact log-rank test (1-sided)
was used to compare the cumulative incidence of conversion to abnormal TCD velocity. The
exact Wilcoxon-Mann-Whitney test was used to compare the other secondary outcomes of
longitudinal TCD velocity changes, acute events, and standardized z-scores for weight,
height, and body mass index (BMI).

Am J Hematol. Author manuscript; available in PMC 2016 December 01.
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RESULTS
Participant Characteristics and Treatment Allocation
During the period of study enrollment from May 2012 to August 2013, a total of 1234
children received TCD screening across all three participating sites. There were 1062 (86%)
children with normal, 115 (9%) with conditional, and 24 (2%) with abnormal TCD
velocities, while 33 (3%) were technical failures (Figure 1).

Author Manuscript

Among the 115 children with conditional TCD exams identified during screening, 38
enrolled (18 from Jamaica, 13 from Brazil, and 7 from the US) and 22 were randomized to
either hydroxyurea or observation. There were 4 children who dropped out during screening
(due to not having a confirmatory TCD), while 12 were in screening at the time of study
closure (Figure 1). The median age at enrollment was 5.4 years (range 2.7 to 9.8 years).
Most participants were female (25/38) and their self-reported races were 28 black and 10
white, reflecting the demographics of the international clinical sites. Genotypes included
HbSS (36), HbSβ0-thalassemia (1), and HbSD (1). The demographics and laboratory
findings at baseline are shown in Table 1.
Premature Study Termination

Author Manuscript

There was a regulatory delay of 18 months preventing importation of the study drug
(hydroxyurea) at one site (HEMORIO). This delay was due to numerous administrative
difficulties in obtaining formal approval by ANVISA (Agência Nacional de Vigilância
Sanitária), the Brazilian government agency responsible for authorizing the entry of study
drugs into the country. The SCATE study opened for enrollment in May 2012, and in
August 2013 the study was suspended for new enrollments and randomization by the
sponsor for slow patient accrual. The study was terminated in January 2014 due to slow
accrual and the unlikelihood of meeting the study’s enrollment target and primary endpoint
within the timeframe of funding. Due to the administrative delay in obtaining drug approval
in Brazil, 2 of the 11 children randomly allocated to the treatment arm (hydroxyurea) did not
initiate study drug as per protocol.
Hematological Effects of Hydroxyurea

Author Manuscript

The median MTD for the 9 participants who received hydroxyurea was 25 mg/kg/day (range
20 – 35 mg/kg/day). Calculated % adherence, based on data from 92 of 112 total study visits
for those who were randomized and received hydroxyurea, was 100% (for both mean and
median). Exit versus baseline median differences in hematological indices for children
receiving hydroxyurea showed expected significant increases in Hb concentration, HbF, and
MCV, along with significant reductions in WBC and ANC in comparison with those who
did not receive hydroxyurea (Table 2). There were no significant differences in renal or
hepatic function tests between the treatment arms.
Primary Study Endpoint
The cumulative incidences of conversion from conditional to abnormal TAMV were 9%
(95% CI 0 to 35%) and 47% (95% CI 6 to 81%) in the hydroxyurea and observation arms
after 15 months, respectively (p = 0.16, Figure 2A). However, none of the participants
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assigned to the hydroxyurea arm who actually received the drug converted to abnormal TCD
velocities, whereas three in the observational arm did (supplemental Table 1). In post-hoc
analysis according to treatment received, hydroxyurea treatment was associated with a
significantly lower risk of conversion to abnormal TAMV after 15 months, 0% versus 50%
(95% CI 9 to 82%), (p = 0.02, Figure 2B).
Secondary Endpoints
All secondary endpoints were evaluated using the intention-to-treat analysis and compared
from randomization to last observation. After a mean of 10.1 months (median 8.7, range 0.5
to 17 months), participants randomized to the hydroxyurea arm had a mean reduction of
TAMV values of 15.5 cm/sec (95% CI -32.0 to 1.1 cm/sec), whereas those in the
observation arm had a mean increase in velocity of 10.2 cm/sec (95% CI -4.8 to 25.2 cm/
sec) (p = 0.02, Figure 3).

Author Manuscript

No strokes or transient ischemic attacks occurred. The only three new neurological events
were dizziness (one event in the hydroxyurea arm) and headaches (one in each arm), with no
significant difference between the two arms. Vaso-occlusive events (pain and acute chest
syndrome) were more common in the observation arm than in the hydroxyurea arm (5
versus 2, respectively), but not significantly different. Two cases of acute splenic
sequestration occurred, one in each arm.
Due to the early study termination, HRQOL was not sufficiently collected at study exit,
therefore due to insufficient data points, no analyses could be performed regarding changes
in HRQOL during the study.

Author Manuscript

Growth parameters of children from all 3 sites plotted within normal limits throughout the
study when using the World Health Organization Child Growth Standards (http://
www.who.int/childgrowth). There was no significant difference between the hydroxyurea
and observation arms in the z-scores for weight, height, and BMI at baseline and last followup (Supplemental Table 2).
Adverse Events and Drug Toxicity

Author Manuscript

One subject on the hydroxyurea arm had one episode of transient neutropenia (ANC <1.0 ×
109/L), vs. none on the observation arm. There were two cases of reticulocytopenia with
worsened anemia (one in each arm), and no thrombocytopenia. There were two cases of
parasite infestation (both hookworm), one in each arm of the study, both treated and with
complete resolution of symptoms. Among those randomized to hydroxyurea who actually
received the drug, only one required blood transfusion (due to an episode of worsened
anemia during influenza B infection marrow suppression), and three subjects not treated
with hydroxyurea received erythrocyte transfusions (two secondary to acute chest syndrome
and one due to exacerbated anemia in the setting of a viral illness) (p=NS).

DISCUSSION
To our knowledge, SCATE is the first international NHLBI-sponsored Phase III randomized
multi-center study in pediatric SCA involving limited-resource countries. Because the study
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was closed early by the sponsor despite active patient accrual and screening, there were
insufficient data to demonstrate a significant reduction in the cumulative incidence of
conversion from conditional to abnormal TCD velocities using intention-to-treat analysis.
When considering only those who received hydroxyurea (post-hoc analysis), however, there
was a significant difference in cumulative incidence of conversion from conditional to
abnormal TCD velocities. In addition, we observed that hydroxyurea treatment significantly
reduced conditional TCD velocities, an important finding suggested by retrospective and
single-arm observational studies.(8-13) SCATE extends these prior observations by
demonstrating prospectively in a randomized phase III trial that hydroxyurea reduces TCD
velocities and may, thereby, lower the risk of primary stroke. By sparing the commonly
observed conversion to abnormal TCD elevation, hydroxyurea therapy for conditional TCD
velocities could obviate the need for chronic and indefinite transfusion therapy in many
young patients with SCA, which represents an important cost-savings to the medical systems
of both low- and high-resource countries.
While hydroxyurea is the only commercially available drug for the treatment of SCA, and
can now be offered to most adults and children 9 months and older,(16) it is far from the
standard of care. Hydroxyurea is still largely unavailable in many countries and thus
underutilized, especially in resource-poor areas of the world. To help the impact of
hydroxyurea treatment be fully realized by the global sickle cell disease community, it is
important to gather prospective data regarding its safety and efficacy in more geographical
locations and clinical settings, which will ultimately define its future indications and
motivate its broader use.

Author Manuscript

Children with conditional TCD velocities represent a group of patients for whom treatment
is not formally recommended (as opposed to those with abnormal TCD velocities) and
therefore remain untreated despite an elevated risk for a primary stroke. The cumulative
conversion rate in our patient sample was higher than in prior reports (30 and 50% versus 10
and 23% at 12 and 18 months, respectively).(5) This difference likely reflects the smaller
sample size of this study, but also the fact that our populations derive from different
countries, possibly adding genetic variability that contributed to the higher cumulative
conversion rates.

Author Manuscript

Hydroxyurea induces fetal hemoglobin production and decreases intracellular HbS polymers
within sickle erythrocytes.(17) Hydroxyurea has a number of additional beneficial effects
besides induction of HbF, including decreased neutrophil and reticulocyte counts caused by
marrow cytotoxicity, interference with red blood cell and leukocyte adhesion to the
endothelium,(18;19) reduction of inflammatory cytokines,(20) and increased release of the
vasodilator, nitric oxide.(21) Clinical benefits of hydroxyurea have been shown in both
children and adults through reduction of frequency of pain and acute chest syndrome
episodes.(12;22;23) Similar to prior studies in children with SCA, laboratory benefits from
hydroxyurea in the SCATE trial also included increases in Hb concentration, HbF, MCV,
and reduction in ANC.(12;24) The beneficial effect of increasing the Hb concentration in the
hydroxyurea-treated arm may have contributed to the observed TAMV reduction. The use of
hydroxyurea in SCA is especially attractive for low-resource settings due to its ease of oral
administration, potential for reducing medical cost, and safety profile.(25) In the SCATE
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study, toxicities from hydroxyurea were uncommon and no different than reported in other
pediatric populations (<10% severe neutropenia and reticulocytopenia).(26-29) Other
adverse events during the study (neurological and non-neurological) were also rare and not
observed in any greater frequency than prior studies.(24;26)

Author Manuscript

The SCATE study explored a new paradigm for collaborative multi-center clinical research
in SCA. Although prematurely interrupted, SCATE highlighted the challenges and
opportunities for international collaboration. High quality and important scientific questions
can and should be answered without limitation of geographical borders or economic status
of a nation. International collaboration facilitates SCA clinical trials for which large sample
sizes are required, and not easily attained with the relatively smaller number of patients in
North America and Europe. Inclusion of countries in Africa, South and Central America
may significantly increase the pool of study participants, although the complexity of such
trials may also increase.(30) Furthermore, in developing nations, where the burden of SCA
is far greater than in the developed world, collaborative research participation provides
overall benefits from improved standards of care, which are likely to impact care beyond the
objectives of the study.

Author Manuscript

International collaborative research involving developing countries is an important goal of
the NHLBI and the American Society of Hematology, particularly for research in SCA.
(31;32) Collaborative research between resource-rich and resource-limited countries brings
many opportunities to further research expertise and to improve clinical care in
underprivileged areas of the world.(33) This study had many unique design features and
challenges, among which was the enrollment of children from three different regions of the
world with different laws and regulatory governance. This was an ambitious study that
included centers with large numbers of children with SCA from both developed and
developing countries. SCATE followed the same rigorous standards of research in all
participating countries and scientifically investigated a potential new indication for
hydroxyurea therapy.
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Our study, although important in addressing the feasibility of conducting rigorously
designed international clinical trials, had a limited final sample size for analysis, which
hindered our ability to reach the primary study endpoint. Of the 115 targeted enrollment for
SCATE, only 38 had enrolled (33%) at the time of study closure. Barriers to study
enrollment are multi-factorial, including investigator-patient mistrust, trial design, and
imbalance of perceived risks and benefits.(34-36) In SCATE, there were added complexities
related to study design, language differences, and prolonged government and regulatory
approvals of the protocol and drug importation, which hindered the ability to provide study
treatment. Wider use of hydroxyurea also played a role at the North American site, reducing
the pool of eligible patients. Because reduction in the TAMV was observed in subjects from
only 2 sites, generalizability of our findings is limited. Despite its limitations, an important
strength of SCATE includes the establishment of an infrastructure that allowed high-quality
research for this trial but also future trials, using the highest scientific standards. Global
efforts, such as that of the Global Sickle Cell Disease network (http://
www.globalsicklecelldisease.org) should build on the experience of the SCATE trial to
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create future successful international studies that will answer relevant questions for
individuals living with SCA worldwide.
In summary, we demonstrated in a phase III randomized clinical trial that hydroxyurea
reduces TAMV in children with SCA and conditional TCD velocities. Hydroxyurea should
be considered for treatment of children with conditional TCD velocities. Future international
multicenter studies should build on the lessons learned through SCATE to develop
additional and relevant clinical trials for people living with SCA.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Consort diagram of the SCATE study

* These 12 subjects were either not yet confirmed or already centrally confirmed as
conditional TCD, but not randomized due to early study suspension and later study closure.
**Two subjects did not receive hydroxyurea due to drug unavailability at one of the sites.
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Figure 2. Cumulative incidence of conversion to abnormal TCD

Author Manuscript

B> A. In the intention-to-treat analysis, conversion to abnormal TCD velocity was higher in
the observation arm, but not statistically significant (p=0.17). B. In the post-hoc as-treated
analysis, conversion to abnormal TCD velocity was significantly higher in the observation
arm (p=0.02).
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Figure 3. Change in TCD velocity according to treatment

B> Children randomized to hydroxyurea had a mean reduction of 15.5 cm/sec, whereas
those on the observation arm had a mean increase of 10.2 cm/sec (p=0.02).
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Table 1

Author Manuscript

Patient Characteristics at Baseline.
Variable

Randomization arm
Hydroxyurea (N=11)

Observation (N=11)

6.2 (2.4)

6.6 (1.5)

Males

4 (36)

4 (36)

Females

7 (64)

7 (64)

Latino

2 (18)

3 (27)

Non-Hispanic

9 (82)

8 (73)

Black

10 (91)

9 (82)

White

1 (9)

2 (18)

11 (100)

10 (91)

0 (0)

1 (9)

Hb (g/dL)

7.5 (0.9)

7.7 (1.0)

MCV (fL)

Age (years)

Gender (n,%)

Ethnicity (n,%)

Author Manuscript

Race (n,%)

Genotype (n,%)
HbSS
HbSβ0thalassemia
Hematologic indices

Author Manuscript

85.9 (5.0)

84.9 (10.8)

ARC

(×109/L)

316.8 (73.22)

381.3 (139.73)

WBC

(×109/L)

14.2 (4.0)

13.1 (4.9)

ANC

(×109/L)

5.9 (2.0)

4.9 (1.9)

474.2 (126.2)

388.1 (151.8)

9.9 (6.7)

9.4 (6.1)

Overall TAMV (cm/sec)

183.5 (8.5)

181.8 (6.4)

Right side TAMV (cm/sec)

167.0 (15.1)

172.7 (14.9)

Left side TAMV (cm/sec)

175.3 (3.9)

174.5 (15.6)

Platelets

(×109/L)

HbF (%)
TCD Values

Notes: ANC: absolute neutrophil count, Hb: hemoglobin, MCV: mean corpuscular volume, ARC: absolute reticulocyte count, WBC: white blood
cell count, TAMV: time-averaged mean velocity. Results presented as mean (SD), unless otherwise specified. There were no significant differences
between both arms.
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312.6

11.9

6.1

460.0

11.8

20.6

113.6

ARC
(×109/L)

WBC
(×109/L)

ANC
(×109/L)

Platelets
(×109/L)

HbF
(%)

Weight
(Kg)

Height
(cm)
91.1

13.2

0.7

256.0

3.7

9.6

209.7

77.9

6.4

Min

135.2

25.3

20.4

723.0

10.7

20.4

473.0

93.2

9.4

Max

121.1

22.2

18.8

410.0

2.7

6.7

316.7

95.7

8.4

Median

102.0

15.1

3.0

179.0

1.3

3.8

186.1

83.2

7.0

Min
11.7

Max

142.8

28.3

34.0

642.0

7056.0

29.0

414.0

102.0

Last Follow-up

6.8

2.5

8.9

−76.0

−2.2

−4.6

22.7

8.7

1.6

Median

Change*

121.3

19.5

9.8

411.0

4.5

12.4

373.0

84.8

7.5

Median

103.6

16.2

1.1

111.0

2.5

5.6

147.2

66.2

6.7

Min

Baseline

130.5

30.5

19.7

634.0

8.3

23.9

600.2

106.5

10.2

Max

125.0

21.9

9.2

376.0

7.4

13.2

326.7

84.0

7.0

Median

107.0

17.0

2.3

127.0

3.9

6.8

261.0

70.0

5.0

Min
9.5

Max

137.3

37.8

19.3

469.0

5762.0

19.0

617.0

102.0

Last Follow-up

Observation Arm (N=11)

3.8

1.8

0.3

−35.0

1.4

1.3

−33.2

1.0

−0.5

Median

Change*

0.22

0.51

0.002

0.56

0.0473

0.0652

0.76

0.0014

<0.0001

P-Value

Change refers to last follow up minus baseline value. Comparison were also made between subjects who actually received hydroxyurea (n=9) versus those who did not (n=13), and the median change for
the following variables showed significant difference: Hb (p<0.0001), MCV (p=0.003), WBC (p=0.03), ANC (p=0.003), and HbF (p < 0.0001).

*

Note: P-values are calculated with the exact Wilcoxon-Mann-Whitney test comparing the exit versus entry differences between median values in the hydroxyurea and observation arms.

86.5

7.41

Hb
(g/dL)

MCV
(fL)

Median

Variable

Baseline

Hydroxyurea Arm (N=11)

Comparisons between Entry and Exit Variables between Arms as Randomized.
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